United States Drug Patent 7,772,178: Scope, Claims, and Landscape Analysis
Executive Summary
United States Patent 7,772,178, titled "Formulations of 1-[3-(5-chloro-1H-indazol-1-yl)-1H-pyrazol-4-yl]-3-(2-fluorophenyl)urea and related compounds," was granted on August 10, 2010. This patent covers specific crystalline forms and formulations of axitinib, a tyrosine kinase inhibitor used in the treatment of advanced renal cell carcinoma. The patent's claims define distinct polymorphic forms, their preparation, and pharmaceutical compositions. The patent landscape surrounding axitinib is characterized by a primary patent for the compound itself, followed by subsequent patents addressing specific formulations, polymorphs, and manufacturing processes. The expiry of the primary patent will lead to generic competition, while the formulation and polymorph patents may extend market exclusivity for specific product versions.
What is the Core Technology Protected by Patent 7,772,178?
Patent 7,772,178 protects specific crystalline forms of axitinib, a small molecule tyrosine kinase inhibitor. The patent's focus is on novel polymorphic forms and their pharmaceutical compositions, designed to improve the drug's stability, bioavailability, and manufacturing characteristics.
The active pharmaceutical ingredient (API) is identified as 1-[3-(5-chloro-1H-indazol-1-yl)-1H-pyrazol-4-yl]-3-(2-fluorophenyl)urea, the chemical name for axitinib.
The patent asserts that these specific crystalline forms exhibit advantageous properties compared to other potential forms or amorphous material, potentially impacting drug product performance.
What are the Key Claims of Patent 7,772,178?
The claims in Patent 7,772,178 are structured to define specific crystalline forms of axitinib and their use in pharmaceutical compositions.
Claim 1: This independent claim defines a specific crystalline form of axitinib, characterized by its X-ray powder diffraction (XRPD) pattern. It lists specific peaks and their relative intensities, identifying a particular polymorphic form.
Claim 2: This claim is dependent on Claim 1 and further defines the crystalline form by specifying a particular range of d-spacings from the XRPD pattern.
Claim 3: This claim is also dependent on Claim 1, providing additional characterization of the crystalline form using parameters such as differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). It specifies temperature ranges for endothermic events and weight loss.
Claim 4: This claim defines a process for preparing the crystalline form claimed in Claim 1. It outlines specific solvent systems and crystallization conditions.
Claim 5: This claim is directed to a pharmaceutical composition comprising the crystalline form of axitinib claimed in Claim 1 and a pharmaceutically acceptable carrier.
Claim 6: This claim is dependent on Claim 5 and specifies the concentration of the axitinib crystalline form in the pharmaceutical composition.
Claim 7: This claim is dependent on Claim 5 and further defines the composition by specifying the type of pharmaceutically acceptable carrier, such as a tablet or capsule.
Claim 8: This claim is dependent on Claim 5 and specifies a particular dosage form, such as an oral solid dosage form.
Claim 9: This claim is directed to a method of treating a disease, such as advanced renal cell carcinoma, comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline form of axitinib claimed in Claim 1 or the pharmaceutical composition claimed in Claim 5.
What are the Specifications and Technical Details?
Patent 7,772,178 provides detailed technical specifications to define the protected crystalline forms.
X-ray Powder Diffraction (XRPD) Data:
The patent provides specific XRPD peaks, typically presented as 2θ angles and relative intensities, which are critical for identifying and distinguishing crystalline polymorphs. For example, a specific form might be characterized by peaks at certain angles with defined intensity ratios. These are crucial for confirming the presence of the patented polymorph.
Differential Scanning Calorimetry (DSC) Data:
DSC data is used to characterize the thermal properties of the crystalline forms, such as melting points and polymorphic transformations. The patent would specify characteristic endothermic events (heat absorption) occurring within defined temperature ranges. This helps differentiate between polymorphs that may have different thermal stabilities or transition behaviors.
Thermogravimetric Analysis (TGA) Data:
TGA measures the weight loss of a sample as a function of temperature. This is used to identify the presence of residual solvents or water within the crystalline lattice. The patent would specify the temperature range over which significant weight loss occurs, indicating the absence or low levels of volatile components.
Particle Size Distribution:
While not always explicitly a claim element for polymorphs themselves, particle size is a critical specification for pharmaceutical formulations. The patent might allude to desired particle size ranges for optimal formulation performance, or manufacturing processes described could yield specific particle size profiles.
Stability Data:
The underlying rationale for protecting specific polymorphs is often their enhanced stability. The patent may implicitly or explicitly reference data demonstrating improved stability against degradation, moisture uptake, or polymorphic conversion compared to other forms.
Manufacturing Process Parameters:
Claims related to the preparation of the crystalline forms detail specific solvent systems, temperatures, cooling rates, seeding techniques, and purification steps. These parameters are essential for reproducible manufacturing of the patented polymorph. For instance, a claim might specify the use of a particular mixture of organic solvents and water at a controlled temperature for crystallization.
What is the Patent Landscape for Axitinib?
The patent landscape for axitinib is characterized by a foundational patent covering the compound itself, followed by patents protecting specific aspects of its development, including formulations and polymorphic forms.
Foundational Compound Patent:
The original patent for axitinib itself, covering the chemical structure and its basic therapeutic utility, is the cornerstone. Once this patent expires, it generally opens the door for generic manufacturers to produce the active ingredient. For axitinib, the primary compound patent is EP 1 408 073 B1 (and its US counterparts), with an expiry date of December 3, 2023, in Europe, and its US equivalents around the same period.
Formulation and Polymorph Patents:
Patent 7,772,178 falls into this category, protecting specific crystalline forms (polymorphs) of axitinib and pharmaceutical compositions containing them. Such patents are often filed after the initial compound patent and can extend market exclusivity by protecting specific ways of delivering the drug or improving its properties.
- US Patent 7,772,178: Specifically protects certain crystalline forms and pharmaceutical compositions of axitinib. This patent has an expiration date of August 10, 2027 (20 years from filing date, considering potential patent term adjustments).
- Other Related Patents: There are likely other patents related to axitinib, covering:
- Manufacturing Processes: Novel or improved methods for synthesizing axitinib or its intermediates.
- Specific Dosing Regimens: Patents might claim specific methods of use or dosing schedules that offer a therapeutic advantage.
- Combinations: Patents covering axitinib in combination with other therapeutic agents.
- Methods of Treatment: Patents claiming the use of axitinib for specific indications or patient populations.
Impact of Expiry Dates:
The expiry of the foundational compound patent allows for the market entry of generic axitinib. However, the survival of later-filed patents, such as US 7,772,178, can complicate generic entry. Generic manufacturers must ensure they do not infringe these later patents. This often involves developing non-infringing crystalline forms or formulations, or waiting for these patents to expire.
Generic Entry Strategy:
Generic companies will assess the validity and enforceability of patents like US 7,772,178. They may challenge these patents through litigation or seek to develop alternative crystalline forms or manufacturing processes that circumvent the patented claims. The expiry of US 7,772,178 on August 10, 2027, is a critical date for generic manufacturers aiming to market products that utilize the specific crystalline forms described within.
What is the Expected Impact on Market Competition and Pricing?
The expiry of the primary compound patent for axitinib has already opened pathways for generic competition. However, the existence and expiry dates of secondary patents, such as US 7,772,178, significantly influence the timing and nature of this competition.
Post-Compound Patent Expiry:
Following the expiry of the foundational patent, generic manufacturers can produce and market axitinib. This typically leads to a substantial decrease in drug prices due to increased competition.
Impact of Formulation/Polymorph Patents (US 7,772,178):
- Delayed Entry for Specific Forms: Generic versions seeking to utilize the exact crystalline forms protected by US 7,772,178 cannot be marketed until August 10, 2027, unless this patent is successfully challenged or invalidated.
- Alternative Generic Products: Generic companies can still launch products using axitinib if they are produced from a different, non-infringing crystalline form or if they use a different formulation approach not covered by patent 7,772,178. This can lead to a fragmented generic market where different products offer varying characteristics.
- Price Differentiation: Products infringing on the patent will be delayed, potentially allowing the innovator product (or generics using non-infringing forms) to maintain a higher price point for a longer period. Once the patent expires, and assuming successful generic entry with the protected forms, prices are expected to fall further.
- Litigation Risk: Generic manufacturers planning to market axitinib products that might infringe on patent 7,772,178 face potential litigation from the patent holder. This risk is a significant consideration in market entry strategies.
Overall Pricing Trend:
The overall trend will be towards price erosion, driven by generic entry. However, the specific timeline and magnitude of price reductions will be influenced by the ability of generic manufacturers to navigate or overcome patents like US 7,772,178. The expiry of this patent in 2027 will likely unlock further price reductions and market access for specific, potentially more stable or bioavailable, formulations of axitinib.
Key Takeaways
- United States Patent 7,772,178 protects specific crystalline forms of axitinib and their pharmaceutical compositions, not the axitinib molecule itself.
- The patent's claims define these forms using XRPD, DSC, and TGA data, along with manufacturing processes and pharmaceutical compositions.
- The patent is set to expire on August 10, 2027, impacting the market entry of generic axitinib products that utilize the claimed crystalline forms.
- While the primary compound patent for axitinib has expired, US 7,772,178 can extend market exclusivity for specific product versions until its expiry.
- Generic manufacturers must carefully assess the claims of US 7,772,178 to avoid infringement and may need to develop alternative crystalline forms or formulations.
Frequently Asked Questions
-
When does United States Patent 7,772,178 expire?
United States Patent 7,772,178 expires on August 10, 2027.
-
Does Patent 7,772,178 cover the drug axitinib itself, or specific aspects of it?
Patent 7,772,178 covers specific crystalline forms of axitinib and pharmaceutical compositions containing these forms, rather than the axitinib molecule in general.
-
Can generic versions of axitinib be sold before August 10, 2027?
Generic versions of axitinib can be sold before August 10, 2027, if they do not infringe on the specific claims of patent 7,772,178, for instance, by using a different crystalline form or formulation. However, products incorporating the patented forms are restricted until the patent's expiry.
-
What technical data is used to define the protected crystalline forms in Patent 7,772,178?
The patent defines the protected crystalline forms primarily through X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) data, and thermogravimetric analysis (TGA) data.
-
What is the significance of this patent for future market competition of axitinib?
This patent is significant because it can delay the market entry of generic axitinib products that utilize the specifically claimed crystalline forms until its expiry in 2027, potentially maintaining higher prices for innovator or alternative generic products during this period.
Citations
[1] U.S. Patent No. 7,772,178 (filed Dec. 17, 2004) (issued Aug. 10, 2010).
[2] European Patent EP 1 408 073 B1 (filed Dec. 2, 2003) (granted Dec. 3, 2008).
